Medtronic Sale of Subsidiary Stock increased by 2.5% to $164.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 2.4%, from $168.00M to $164.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
Positive proceeds indicate successful monetization of assets, while the absence of such activity suggests a focus on retaining control of existing subsidiaries.
This captures the cash proceeds or financial impact resulting from the sale of equity interests in a subsidiary. It refl...
Often reported under 'Proceeds from sale of investments' or 'Divestitures' in the investing section.
is_wmt_sale_of_subsidiary_stock| Q2 '21 | Q3 '21 | Q4 '21 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q4 '23 | Q2 '24 | Q3 '24 | Q4 '24 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $111.00M | $163.00M | $70.00M | $43.00M | $110.00M | $56.00M | $77.00M | $72.00M | $57.00M | $89.00M | $143.00M | $168.00M | $95.00M | $160.00M | $164.00M |
| QoQ Change | — | +46.8% | -57.1% | -38.6% | +155.8% | -49.1% | +37.5% | -6.5% | -20.8% | +56.1% | +60.7% | +17.5% | -43.5% | +68.4% | +2.5% |
| YoY Change | — | — | — | -61.3% | -32.5% | -20.0% | +79.1% | -34.5% | +1.8% | +15.6% | +98.6% | +194.7% | +6.7% | +11.9% | -2.4% |